AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A process for obtaining cryoprecipitable proteins comprising:
(a) contacting a composition of the cryprecipitable protein[[(s)]] of interest with a stabilizing and solubilizing formulation comprising a mixture of arginine, at least one hydrophobic amino acid and trisodium ~~phosphate~~citrate; and
(b) transforming said protein[[(s)]] composition into a freeze-dried ~~form~~protein; and
(c) performing a virus inactivation step by heat treatment of said freeze-dried ~~proteins~~protein.

2. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 1, ~~characterized in~~wherein that the formulation consists essentially of the ~~said~~ mixture of arginine, ~~at least one~~the hydrophobic amino acid and the trisodium ~~phosphate~~citrate.

3. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 1, wherein arginine is present in a concentration of from 25 to 50 g/l.

4. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 3, wherein the concentration of arginine is of from 35 to 45 g/l.

5. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 1, wherein the trisodium citrate is present in a concentration of from 0.5 to about 12 g/l.

6. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 1, wherein the hydrophobic amino acid is leucine, iso-leucine or a mixture thereof.

7. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 6, wherein leucine, iso-leucine or mixture thereof are present in a concentration of from 5 to 15 g/l.

8. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 6, wherein the concentration of leucine or iso-leucine or mixture thereof is of from 9 to 11 g/l.

9. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 1, wherein the formulation of step (a) further contains glycine and/or lysine.

10. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 9, wherein glycine and lysine are each present in a concentration of from 1 to 5 g/l.

11. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 9, wherein each of these concentrations of glycine and lysine is ~~of~~ from 1.5 to 2.5 g/l.

12. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 1, wherein ~~the freeze-drying of~~ step (b) is carried out at temperatures between -40°C and -30°C for 48 hours.

13. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 1, wherein ~~the heat treatment of virus inactivation of~~ step (c) is carried out at temperatures between 80°C and 90°C for 72 hours.

14. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 1, further comprising[[ ]], prior to step (a), at least one step of virus inactivation and/or elimination from the ~~said~~ composition of cryoprecipitable protein(s) by solvent-detergent and/or by nanofiltration on filters of 35 nm.

15. **(Cancelled)**

16. **(Currently Amended)** ~~A~~ The process ~~according to~~of claim 1, ~~characterized in that it is applicable to~~wherein said process uses at least one of the proteins selected from the group consisting of Factor VIII, von Willebrand Factor, Factor XIII, fibrinogen and fibronectin.

17. **(Currently Amended)** A concentrate ~~of at least one~~comprising a cryoprecipitable protein comprising ~~the~~ a stabilizing and solubilizing formulation ~~in combination with at least one~~added to the protein prepared by the process according to claim 1.

18. **(Currently Amended)** ~~A~~ The concentrate ~~according to~~of claim 17 ~~intended for therapeutic use~~wherein said concentrate is used as a therapeutic.

19. **(Currently Amended)** ~~A~~ The concentrate ~~according to~~of claim 17, ~~presenting~~ comprising a filterability of about 2 ml/cm² on a filter with a porosity of 0.20 ± 0.02 μm.

20. **(Cancelled)**

21. **(Cancelled)**